Page last updated: 2024-12-10

sb 258585

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SB 258585: is a high affinity ligand at 5-HT(6) receptors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3248571
CHEMBL ID60264
CHEBI ID93418
SCHEMBL ID678180
MeSH IDM0376892

Synonyms (25)

Synonym
4-iodo-n-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide
BRD-K80639402-003-01-1
NCGC00025328-01 ,
tocris-1961
NCGC00025328-02
sb 258585
sb-258585
sb258585
CHEMBL60264
bdbm86428
209480-63-7
sb-258,585
4-iodo-n-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzene-1-sulfonamide
gtpl3232
SCHEMBL678180
CHEBI:93418
4-iodo-n-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzenesulfonamide
unii-54bp69j53f
benzenesulfonamide, 4-iodo-n-(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl)-
54bp69j53f ,
Q855518
sb258585 hydrochloride
benzenesulfonamide, 4-iodo-n-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-
DTXSID801026944
4-iodo-n-(4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)benzenesulfonamide

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
15-lipoxygenase, partialHomo sapiens (human)Potency7.94330.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency28.23200.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki0.00250.00030.37088.1600AID6547
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)0.01900.00170.83815.4200AID762125
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.00250.00020.522910.0000AID239920; AID6547
5-hydroxytryptamine receptor 6Mus musculus (house mouse)Ki0.04230.00030.04230.1140AID444246; AID444247; AID444249; AID444250
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 6Homo sapiens (human)Kb0.00040.00030.00430.0300AID1771807; AID1784742
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID763804Antagonist activity at human recombinant 5HT7 receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced cAMP accumulation at 10 uM pretreated for 10 mins before 5HT addition measured after 1 hr relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
AID1730222Toxicity in mouse C8-D1A astrocytes assessed as reduction in cell viability at 0.25 uM by MTT assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Imidazopyridine-Based 5-HT
AID1730224Glio-protective activity in mouse C8-D1A astrocytes assessed as reduction in DOX-induced toxicity at 0.25 uM pre-incubated for 5 hrs before doxorubicin addition and measured after 3 hrs by MTT assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Imidazopyridine-Based 5-HT
AID234644Selectivity for 5-HT6 receptors with respect to the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT4, 5-HT7, Alpha-1B, D2, D3 receptors.1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.
AID1730226Glio-protective activity in mouse C8-D1A astrocytes assessed as reduction in 6-OHDA-induced toxicity at 0.25 uM pre-incubated for 12 hrs before doxorubicin addition and measured after 24 hrs by MTT assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Imidazopyridine-Based 5-HT
AID762126Antagonist activity at human 5-HT6 receptor expressed in human HeLa cells assessed as inhibition of 5-HT-induced cAMP accumulation at 10 uM pretreated for 10 mins before 5-HT addition measured after 30 mins2013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Synthesis and the 5-HT6 receptor antagonistic effect of 3-arylsulfonylamino-5,6-dihydro-6-substituted pyrazolo[3,4]pyridinones for neuropathic pain treatment.
AID1784742Antagonist activity at human 5HT6R expressed in 1321N1 cells assessed as inhibition of IBMX-induced cAMP production measured after 30 mins by TR-FRET assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT
AID444246Antagonist activity at mouse wild type 5HT6 receptor expressed in COS7 cells assessed as inhibition of serotonin-induced cAMP accumulation by HTRF assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
AID1730223Toxicity in mouse C8-D1A astrocytes assessed as reduction in cell viability by MTT assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Imidazopyridine-Based 5-HT
AID444247Antagonist activity at mouse 5HT6 receptor C3.36A mutant expressed in COS7 cells assessed as inhibition of serotonin-induced cAMP accumulation by HTRF assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
AID762125Antagonist activity at human 5-HT6 receptor expressed in human HeLa cells assessed as inhibition of 5-HT-induced cAMP accumulation pretreated for 10 mins before 5-HT addition measured after 30 mins2013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Synthesis and the 5-HT6 receptor antagonistic effect of 3-arylsulfonylamino-5,6-dihydro-6-substituted pyrazolo[3,4]pyridinones for neuropathic pain treatment.
AID6547Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.
AID763805Antagonist activity at human recombinant 5HT4 receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced cAMP accumulation at 10 uM pretreated for 10 mins before 5HT addition measured after 1 hr relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
AID239920Binding affinity for human 5-hydroxytryptamine 6 receptor2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists.
AID1730227Glio-protective activity in mouse C8-D1A astrocytes assessed as reduction in 6-OHDA-induced toxicity at 0.25 uM pre-incubated for 12 hrs before doxorubicin addition and measured after 24 hrs by LDH assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Imidazopyridine-Based 5-HT
AID444249Antagonist activity at mouse 5HT6 receptor W6.48A mutant expressed in COS7 cells assessed as inhibition of serotonin-induced cAMP accumulation by HTRF assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
AID763807Antagonist activity at human recombinant 5HT6 receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced cAMP accumulation at 10 uM pretreated for 10 mins before 5HT addition measured after 1 hr relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.
AID1771807Antagonist activity at human 5HT6 receptor expressed in human 1321N1 cells assessed as inhibition of serotonin-induced cAMP accumulation incubated for 30 mins by TR-FRET assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT
AID1771842Inhibition of BuChE in human plasma using BTC as substrate at 10 uM preincubated with enzyme for 5 mins followed by substrate addition for 5 mins by Ellman's method relative to control2021European journal of medicinal chemistry, Dec-05, Volume: 225Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT
AID1760281Antagonist activity at human 5-HT6 expressed in human 1321N1 cells incubated for 30 mins by LANCE Ultra cAMP kit-based TR-FRET assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Chlorine substituents and linker topology as factors of 5-HT
AID444248Antagonist activity at mouse 5HT6 receptor C5.43A mutant expressed in COS7 cells assessed as inhibition of serotonin-induced cAMP accumulation by HTRF assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
AID444250Antagonist activity at mouse 5HT6 receptor F6.52A mutant expressed in COS7 cells assessed as inhibition of serotonin-induced cAMP accumulation by HTRF assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
AID444251Antagonist activity at mouse 5HT6 receptor N6.55A mutant expressed in COS7 cells assessed as inhibition of serotonin-induced cAMP accumulation by HTRF assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.
AID1730225Glio-protective activity in mouse C8-D1A astrocytes assessed as reduction in DOX-induced toxicity at 0.25 uM pre-incubated for 5 hrs before doxorubicin addition and measured after 3 hrs by LDH release assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Imidazopyridine-Based 5-HT
AID1760282Agonist activity at human 5-HT6 expressed in human 1321N1 cells assessed as Emax incubated for 30 mins by LANCE Ultra cAMP kit-based TR-FRET assay relative to serotonin2020European journal of medicinal chemistry, Oct-01, Volume: 203Chlorine substituents and linker topology as factors of 5-HT
AID1345170Human 5-HT6 receptor (5-Hydroxytryptamine receptors)2000British journal of pharmacology, Aug, Volume: 130, Issue:7
Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (2.63)18.2507
2000's10 (26.32)29.6817
2010's20 (52.63)24.3611
2020's7 (18.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.75 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]